公开(公告)号：US09642873B2

公开(公告)日：2017-05-09

申请号：US13695073

申请日：2011-05-04

申请人： Patrick Y. Lu ,  Vera Simonenko ,  David Evans ,  John J. Xu

发明人： Patrick Y. Lu ,  Vera Simonenko ,  David Evans ,  John J. Xu

IPC分类号： C07H21/04 ,  C07H21/02 ,  A61K48/00 ,  A61K31/713 ,  C12N15/113 ,  A61K45/06

CPC分类号： A61K31/713 ,  A61K45/06 ,  C07H21/02 ,  C12N15/113 ,  C12N15/1136 ,  C12N15/1137 ,  C12N2310/14 ,  C12N2320/11 ,  C12N2320/31 ,  C12Y114/99001

摘要： The present invention provides compositions and methods for using combinations of TGFβ1 and Cox-2 inhibitors and TGFβ1 and Hoxb13 inhibitors for the treatment of various medical conditions, including skin scaring due to trauma wounds and surgery, corneal and retina scaring due to injury and surgery, internal organ scaring due to injury and surgery, heart tissue scaring due to heart attack and surgery, and lung, liver, and kidney fibrosis due to inflammation and injury. One example is to use siRNA inhibitors to silence TGFβ1 and Cox-2 at the same time, resulting in significant less scar formation.

公开(公告)号：US09012622B2

公开(公告)日：2015-04-21

申请号：US13141122

申请日：2009-12-31

申请人： Patrick Y. Lu ,  David Evans ,  Jun John Xu

发明人： Patrick Y. Lu ,  David Evans ,  Jun John Xu

IPC分类号： C07H21/04 ,  C12N15/113

CPC分类号： C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N15/1137 ,  C12N15/1138 ,  C12N2310/11 ,  C12N2310/113 ,  C12N2310/17 ,  C12N2320/31 ,  C12N2320/32

摘要： The present invention provides small interfering RNA (siRNA) molecules, compositions containing the molecules, and methods of using the molecules and compositions to treat breast cancer. In one aspect, a multi-targeted siRNAi cocktail is disclosed. The siRNA molecules may be encapsulated in nanoparticles to further enhance their anti-cancer activity. The compositions may also be used in combination with other anti-cancer agents, such as bevacizumab.

摘要翻译： 本发明提供小干扰RNA（siRNA）分子，含有该分子的组合物，以及使用该分子和组合物治疗乳腺癌的方法。 一方面，公开了一种多靶向siRNAi混合物。 siRNA分子可以包封在纳米颗粒中以进一步增强其抗癌活性。 组合物也可以与其它抗癌剂如贝伐珠单抗联合使用。

公开(公告)号：US20110124710A1

公开(公告)日：2011-05-26

申请号：US13005688

申请日：2011-01-13

申请人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

发明人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

IPC分类号： C07H21/02 ,  A61K31/7105 ,  C12N5/09 ,  A61P35/04

CPC分类号： A61K31/70 ,  A61K9/5146 ,  A61K48/00

摘要： Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

摘要翻译： 提供组合物和方法用于治疗涉及不想要的新血管形成（NV）的疾病。 本发明提供通过选择性抑制促血管生成生物化学途径来控制NV的治疗，包括VEGF通路基因表达的抑制和局部在病理性NV组织的抑制。 提供了包含聚合物缀合物和诱导RNA干扰（RNAi）的核酸分子的组织靶向纳米颗粒组合物。 本发明的纳米颗粒组合物可以单独使用或与其它治疗剂如VEGF途径拮抗剂组合使用。 组合物和方法可用于治疗NV疾病如癌症，眼病，关节炎和炎性疾病。

公开(公告)号：US07534878B2

公开(公告)日：2009-05-19

申请号：US11824085

申请日：2007-06-29

申请人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

发明人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

IPC分类号： C07H21/04 ,  C07H21/02 ,  A61K48/00

CPC分类号： A61K48/00 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/5146 ,  A61K31/70 ,  C12N15/1136 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2320/31 ,  C12N2320/32

摘要： Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

摘要翻译： 提供组合物和方法用于治疗涉及不想要的新血管形成（NV）的疾病。 本发明提供通过选择性抑制促血管生成生物化学途径来控制NV的治疗，包括VEGF通路基因表达的抑制和局部在病理性NV组织的抑制。 提供了包含聚合物缀合物和诱导RNA干扰（RNAi）的核酸分子的组织靶向纳米颗粒组合物。 本发明的纳米颗粒组合物可以单独使用或与其它治疗剂如VEGF途径拮抗剂组合使用。 组合物和方法可用于治疗NV疾病如癌症，眼病，关节炎和炎性疾病。

公开(公告)号：US20240139228A1

公开(公告)日：2024-05-02

申请号：US18484291

申请日：2023-10-10

申请人： Alan Y. LU ,  Huanlong QIN ,  Menghan LIU ,  Patrick Y. LU

发明人： Alan Y. LU ,  Huanlong QIN ,  Menghan LIU ,  Patrick Y. LU

IPC分类号： A61K31/7105 ,  A61K47/10 ,  A61K47/42 ,  A61K48/00 ,  A61P35/00

CPC分类号： A61K31/7105 ,  A61K47/10 ,  A61K47/42 ,  A61K48/00 ,  A61P35/00 ,  C12Q2600/178 ,  G01N33/57419

摘要： A pharmaceutical composition, comprises micro RNAs with or without chemical modification, and a carder suitable for delivery in vivo, the carrier is a branched histidine-lysine polypeptide or modified compound thereof. The pharmaceutical composition is capable of inhibiting the growth of colon cancer by inducing programmed death of cancer cell and further be used for the manufacture of a targeted drug for colorectal cancer treatment.

公开(公告)号：US07893243B2

公开(公告)日：2011-02-22

申请号：US11824084

申请日：2007-06-29

申请人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

发明人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

IPC分类号： C07H21/04 ,  C07H21/02 ,  A61K48/00

CPC分类号： A61K48/00 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/5146 ,  A61K31/70 ,  C12N15/1136 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2320/31 ,  C12N2320/32

摘要： Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

摘要翻译： 提供组合物和方法用于治疗涉及不想要的新血管形成（NV）的疾病。 本发明提供通过选择性抑制促血管生成生物化学途径来控制NV的治疗，包括VEGF通路基因表达的抑制和局部在病理性NV组织的抑制。 提供了包含聚合物缀合物和诱导RNA干扰（RNAi）的核酸分子的组织靶向纳米颗粒组合物。 本发明的纳米颗粒组合物可以单独使用或与其它治疗剂如VEGF途径拮抗剂组合使用。 组合物和方法可用于治疗NV疾病如癌症，眼病，关节炎和炎性疾病。

公开(公告)号：US07781414B2

公开(公告)日：2010-08-24

申请号：US10551667

申请日：2004-04-01

申请人： Patrick Y. Lu ,  Frank Y. Xie ,  Martin C. Woodle ,  Yijia Liu ,  Quinn Q. Tang ,  Jun Xu

发明人： Patrick Y. Lu ,  Frank Y. Xie ,  Martin C. Woodle ,  Yijia Liu ,  Quinn Q. Tang ,  Jun Xu

IPC分类号： A61K31/70 ,  C07H21/04 ,  C07H21/00 ,  C12P19/34

CPC分类号： C12Q1/6886 ,  A61K48/00 ,  A61K2039/53 ,  C07K14/4748 ,  C07K14/475 ,  C07K14/71 ,  C07K16/30 ,  C12N15/111 ,  C12N15/1135 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2320/12 ,  C12Q2600/112 ,  G01N33/57407 ,  G01N2500/00

摘要： The present invention relates to methods for treating cancers by manipulating a target gene expression by up-regulation, silencing and/or down-regulation of the gene, such as EGFR-RP, TRA1, MFGE8, TNFSF13 and ZFP236, respectively. The methods are useful in treating cancers and/or inhibiting tumor growth by enhancing expression of a gene that is validated as a target such as ICT1030, for protein, peptide drug and gene therapy modalities; or by RNA interference to silence and/or down-regulate targets such as ICT1024, ICT1025 and ICT1031 and ICB1003 that are validated for antibody, small molecule and other inhibitor drug modalities.

摘要翻译： 本发明涉及通过分别通过上调，沉默和/或下调基因如EGFR-RP，TRA1，MFGE8，TNFSF13和ZFP236来操纵靶基因表达来治疗癌症的方法。 该方法可用于通过增强作为靶标的基因（例如ICT1030）的蛋白质，肽药物和基因治疗方式的表达来治疗癌症和/或抑制肿瘤生长; 或通过RNA干扰来沉默和/或下调诸如针对抗体，小分子和其他抑制剂药物形态验证的ICT1024，ICT1025和ICT1031和ICB1003的靶标。

公开(公告)号：US07723316B2

公开(公告)日：2010-05-25

申请号：US11824426

申请日：2007-06-29

申请人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

发明人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

IPC分类号： A61K31/70 ,  C12Q1/68 ,  C07H21/04

CPC分类号： A61K48/00 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/5146 ,  A61K31/70 ,  C12N15/1136 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2320/31 ,  C12N2320/32

摘要： Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

摘要翻译： 提供组合物和方法用于治疗涉及不想要的新血管形成（NV）的疾病。 本发明提供通过选择性抑制促血管生成生物化学途径来控制NV的治疗，包括VEGF通路基因表达的抑制和局部在病理性NV组织的抑制。 提供了包含聚合物缀合物和诱导RNA干扰（RNAi）的核酸分子的组织靶向纳米颗粒组合物。 本发明的纳米颗粒组合物可以单独使用或与其它治疗剂如VEGF途径拮抗剂组合使用。 组合物和方法可用于治疗NV疾病如癌症，眼病，关节炎和炎性疾病。

公开(公告)号：US20090118208A1

公开(公告)日：2009-05-07

申请号：US11824084

申请日：2007-06-29

申请人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

发明人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

IPC分类号： C07H21/02 ,  C07H21/00 ,  A61P9/00 ,  A61P35/00 ,  A61K31/7088

CPC分类号： A61K48/00 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/5146 ,  A61K31/70 ,  C12N15/1136 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2320/31 ,  C12N2320/32

摘要： Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.

摘要翻译： 提供组合物和方法用于治疗涉及不想要的新血管形成（NV）的疾病。 本发明提供通过选择性抑制促血管生成生物化学途径来控制NV的治疗，包括VEGF通路基因表达的抑制和局部在病理性NV组织的抑制。 提供了包含聚合物缀合物和诱导RNA干扰（RNAi）的核酸分子的组织靶向纳米颗粒组合物。 本发明的纳米颗粒组合物可以单独使用或与其它治疗剂如VEGF途径拮抗剂组合使用。 组合物和方法可用于治疗NV疾病如癌症，眼病，关节炎和炎性疾病。

公开(公告)号：US20080241198A1

公开(公告)日：2008-10-02

申请号：US11824426

申请日：2007-06-29

申请人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

发明人： Yijia Liu ,  Patrick Y. Lu ,  Martin C. Woodle ,  Frank Y. Xie

IPC分类号： A61K9/00 ,  C07H21/04 ,  C12N15/87 ,  A61P9/00 ,  A61K31/7105

CPC分类号： A61K48/00 ,  A61K9/0019 ,  A61K9/0048 ,  A61K9/5146 ,  A61K31/70 ,  C12N15/1136 ,  C12N15/1138 ,  C12N2310/14 ,  C12N2310/53 ,  C12N2320/31 ,  C12N2320/32

摘要： Compositions and methods are provided for treatment of diseases involving unwanted neovascularization (NV). The invention provides treatments that control NV through selective inhibition of pro-angiogenic biochemical pathways, including inhibition of the VEGF pathway gene expression and inhibition localized at pathological NV tissues. Tissue targeted nanoparticle compositions comprising polymer conjugates and nucleic acid molecules that induce RNA interference (RNAi) are provided. The nanoparticle compositions of the invention can be used alone or in combination with other therapeutic agents such as VEGF pathway antagonists. The compositions and methods can be used for the treatment of NV diseases such as cancer, ocular disease, arthritis, and inflammatory diseases.